Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Agilent Introduces HaloPlex Next-Generation Sequencing Panels

Published: Monday, June 17, 2013
Last Updated: Monday, June 17, 2013
Bookmark and Share
Catalog and custom panels enable rapid, targeted genomics analysis.

Agilent Technologies Inc. has introduced a new series of HaloPlex next-generation sequencing panels targeting specific disease states.

Two catalog products, the HaloPlex Cancer Research Panel and the HaloPlex Cardiomyopathy Research Panel, plus five predesigned research panels for arrhythmia, ICCG genomic regions, X chromosome, Noonan syndrome, and connective tissue disorders are now available.

Used in combination with Agilent’s SureDesign and SureCall software, the new panels enable laboratories to perform integrated data analysis, mapping and reporting with greater confidence, speed and flexibility.

“With the adoption of desktop sequencing, clinical research laboratories are increasingly interested in panels with predesigned content for routine analysis,” said Dr. Berivan Baskin, FACMG, FCCMG, clinical molecular geneticist at Uppsala University Hospital, who worked with Agilent to develop the panels.

Dr. Baskin continued, “These new HaloPlex panels, combined with Agilent’s analysis software, provide comprehensive content with high levels of sensitivity and specificity.”

“Clinical research laboratories commonly lack the time and resources necessary to individually define disease-related genes and incorporate them into their own custom sequencing panels,” said Jacob Thaysen, vice president and general manager of Agilent’s Genomics Solutions Division.

Thaysen continued, “So we have been working closely with industry experts to develop these targeted disease panels to help these laboratories dramatically improve their workflows and research outcomes.”

HaloPlex target-enrichment solutions combine the speed and specificity of polymerase chain reaction-based systems with the scalability and capture-size flexibility of solution-based hybridization formats, eliminating the need for library preparation.

This streamlined sequence-selective solution for next-generation sequencing helps to remove bottlenecks associated with targeted resequencing and eliminate the need for expensive, dedicated instrumentation or laborious protocols.

SureDesign and SureCall software programs are an integral part of Agilent’s complete solutions for next-generation sequencing target enrichment.

SureDesign increases flexibility by allowing HaloPlex panel users to develop custom panels and incorporate additional predesigned genes/regions of interest to suit their laboratory’s individual needs.

SureCall significantly reduces the data analysis hurdles faced by researchers, enabling simple and intuitive variant calling.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Dako, Cell Signalling Tech Partner with Companion Diagnostics
Partnership for development of high-quality, cutting-edge companion diagnostic products for diagnosis and treatment of cancer.
Monday, January 12, 2015
Agilent, Cell Line Genetics Collaborate
Companies to collaborate on high-throughput cell-line characterization services for regenerative medicine, cancer researchers.
Thursday, February 13, 2014
Dr. Emmanuel Barillot Receives Agilent Thought Leader Award
Award will support Dr. Barillot’s Web-based tools for cancer and drug-safety research.
Friday, August 30, 2013
Dako to Offer New Antibody in U.S. to Diagnose Breast Cancer
Dako receives clearance to sell FLEX Monoclonal Rabbit Anti-Human Estrogen Receptor a, Clone EP1 in US.
Monday, April 08, 2013
Agilent Technologies Thought Leader Award Supports Translational Research Program
The award will support Dr DePinho's research into metabolic reprogramming in the earliest stages of cancer.
Monday, March 04, 2013
Agilent Technologies Teams with University of Liverpool's Centre for Genomic Research
Centre for Genomic Research has become the UK's first Certified Service Provider for the Agilent SureSelect Target Enrichment System for next-generation sequencing.
Wednesday, August 08, 2012
Agilent Technologies Collaborates with Gachon University
World-leading research laboratory at Gachon will have access to the latest technologies from Agilent and a beta test site for new solutions.
Monday, July 23, 2012
Agilent Completes Acquisition of Dako, Danish Cancer Diagnostics Company
Acquisition to help strengthen Agilent's position in life sciences.
Thursday, June 28, 2012
Agilent to Acquire Dako for $2.2 Billion
The largest acquisition in Agilent’s history is the next step in their growing role in clinical diagnostics.
Friday, May 18, 2012
Agilent Appoints Molecular Genomics as its First Certified Service Provider for Microarrays in Singapore
Molecular Genomics offers microarray services using the Agilent CGH/SNP microarrays, gene expression, and microRNA products.
Monday, July 25, 2011
Agilent Appoints BGI First Certified Service Provider in China for Target Enrichment System for Next-Gen Sequencing
Certified for all SureSelect XT target enrichment protocols including human all-exon, SureSelect indexing, DNA capture, RNA capture, kinome RNA and custom kits.
Sunday, April 17, 2011
Agilent Technologies Acquire Lab901
Agilent Technologies Inc. announces that it has acquired the Edinburgh-based electrophoresis equipment and consumables company, Lab901.
Thursday, March 03, 2011
Agilent Debuts RNA Target Enrichment, Streamlining Transcriptome Profiling Studies to Advance Cancer and Stem Cell Research
Company has introduced SureSelect RNA Capture Kits, enabling geneticists to focus on specific genomic loci or transcripts of research interest.
Wednesday, February 09, 2011
Agilent Technologies Extends Million-Feature Format to Gene Expression Microarrays
Agilent SurePrint G3 Gene Expression Microarrays provides up to one million features per standard 1-by-3-inch slide for added throughput.
Tuesday, May 18, 2010
Automating Viral RNA Genotyping
Agilent Automation Solutions has released a new applications bulletin that describes an automated system for rapid characterization of pathogens, including for example the Influenza A (H1N1) virus.
Thursday, February 18, 2010
Scientific News
Researchers Develop Classification Model for Cancers Caused by KRAS
Most frequently mutated cancer gene help oncologists choose more effective cancer therapies.
Tolerant Immune System Increases Cancer Risk
Researchers have found that individuals with high immunoCRIT ratios may have an increased risk of developing certain cancers.
Developing a Gel that Mimics Human Breast for Cancer Research
Scientists at the Universities of Manchester and Nottingham have been funded to develop a gel that will match many of the biological structures of human breast tissue, to advance cancer research and reduce animal testing.
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Predictive Model for Breast Cancer Progression
Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.
Specific Variations in RNA Splicing Linked to Breast Cancer
Researchers have identified cellular changes that may play a role in converting normal breast cells into tumors. Targeting these changes could potentially lead to therapies for some forms of breast cancer.
Gene Expression: A Snapshot of Stem Cell Development
New genes found that regulate development of stem cells.
Assessing Cancer Patient Survival and Drug Sensitivity
RNA editing events another way to investigate biomarkers and therapy targets.
Editing Genes to Create HIV Killers
Seattle scientists have managed to genetically transform human cells in the lab from HIV targets to HIV killers, and the technique could have implications for cancer and other diseases.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos